Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs.
about
CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptorsConsistency of the disposition index in the face of diet induced insulin resistance: potential role of FFA.Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.Increase in visceral fat per se does not induce insulin resistance in the canine model.The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.High-fat diet-induced insulin resistance does not increase plasma anandamide levels or potentiate anandamide insulinotropic effect in isolated canine isletsLarge size cells in the visceral adipose depot predict insulin resistance in the canine model.CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogsExenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-DiabetesExcess of the endocannabinoid anandamide during lactation induces overweight, fat accumulation and insulin resistance in adult mice.Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates.Rapid development of cardiac dysfunction in a canine model of insulin resistance and moderate obesity.Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog.Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice.Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.
P2860
Q28610813-8063509B-51EE-4B1D-B3D3-0981342287D6Q33867407-B44CE329-8348-4971-B8F3-30E245A76F62Q34028741-86EFA505-9441-4F3D-AE22-061C78FD8C3BQ34771884-FE0F62AB-E180-4EFD-A9D8-147F0EFDAEFAQ35193287-3E8EB45A-6A6A-400F-B4C0-CEB30C8810E9Q35347646-CE3CD697-B08B-49CB-B93C-4B22DBC037C0Q35581283-A85EEB27-27FF-4386-9814-E57B917670FBQ35993655-873AD02B-0F58-4888-97DD-E895313B30E2Q36072493-99A55661-013D-4809-B65C-C096C59F1D54Q36226578-4ECA4F62-C5BA-43C2-9A3E-98E60E0B2281Q36309433-C065FCBA-9CEA-4A27-91C1-DC79D462F6F5Q37643533-7FA2C772-EFB6-463E-B8D0-31FF80809D1AQ37672590-328019C2-0117-4DFB-BBC1-BCB07F375830Q43445796-52DC5BBD-0226-44B0-8BC1-697C0C84831FQ45288843-C28294B6-98A3-4215-9424-CFCCD9BA6040Q47797514-4B992181-F476-4949-9BCF-1743DD24BD78
P2860
Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Rimonabant prevents additional ...... ring high-fat feeding in dogs.
@en
Rimonabant prevents additional ...... ring high-fat feeding in dogs.
@nl
type
label
Rimonabant prevents additional ...... ring high-fat feeding in dogs.
@en
Rimonabant prevents additional ...... ring high-fat feeding in dogs.
@nl
prefLabel
Rimonabant prevents additional ...... ring high-fat feeding in dogs.
@en
Rimonabant prevents additional ...... ring high-fat feeding in dogs.
@nl
P2093
P2860
P1476
Rimonabant prevents additional ...... ring high-fat feeding in dogs.
@en
P2093
Darko Stefanovski
Isabel R Hsu
Jenny D Chiu
Joyce M Richey
Karyn J Catalano
L Nicole Harrison
Maya Lottati
Orison O Woolcott
Richard N Bergman
P2860
P304
P356
10.1152/AJPENDO.90972.2008
P577
2009-04-14T00:00:00Z